Dynorphin and the Kappa Opioid Receptor’s Role in the Symptomatology of Schizophrenia: A Review of the Evidence

@article{Clark2019DynorphinAT,
  title={Dynorphin and the Kappa Opioid Receptor’s Role in the Symptomatology of Schizophrenia: A Review of the Evidence},
  author={Samuel Clark and Anissa Abi-Dargham},
  journal={Biological psychiatry},
  year={2019}
}

Figures from this paper

The Role of Dynorphin and the Kappa Opioid Receptor in Schizophrenia and Major Depressive Disorder: A Translational Approach.
  • Samuel Clark
  • Psychology, Medicine
    Handbook of experimental pharmacology
  • 2020
TLDR
Current clinical data have shown that the KOR may be an effective target for treating anhedonia, a finding relevant to both schizophrenia and depression, and recommendations are provided for translating preclinical models for schizophrenia and major depressive disorder into the clinic.
A review on emerging drug targets in treatment of schizophrenia.
TLDR
This review explores the functions of different receptors other than dopaminergic systems to treat and manage schizophrenia effectively and provides readers guidance on newer targets related to schizophrenia.
The Kappa Opioid Receptor and the Sleep of Reason: Cortico-Subcortical Imbalance Following Salvinorin-A
TLDR
The salvinorin-A–mediated KOR agonism induced dramatic psychotomimetic effects along with a generalized decrease in cerebral blood flow and electric activity within the cerebral cortex.
Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates.
TLDR
How non-human primates (NHP) studies facilitate the research and development of ligands targeting the KOR, effects of the endogenous opioid peptide, dynorphin A-(1-17), and its analogs in NHP, and pleiotropic effects and therapeutic applications of KOR-related ligands are highlighted.
Opioid use and schizophrenia.
TLDR
Exploration into the relationship between schizophrenia and opiate abuse is still in its infancy and requires a significant amount of future attention to clarify the epidemiology of this comorbidity, neurobiological relationship, shared genetic underpinnings, and possible treatments for both the psychotic symptoms and substance abuse.
Opioid antagonists are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of controlled trials
TLDR
Evidence provides support for further testing in randomized clinical trials of a new class of non-D2-receptor drugs, based on opioid mechanisms, for the treatment of positive and negative symptoms of schizophrenia.
Traumatic Stress-Induced Vulnerability to Addiction: Critical Role of the Dynorphin/Kappa Opioid Receptor System
TLDR
Underlies experimental and clinical results emphasizing the DYN/KOR system as common mechanisms shared by SUD or/and traumatic stress-related pathologies, and suggests KOR antagonist as a new pharmacological strategy to treat this comorbidity.
The Endogenous Opioid System in Schizophrenia and Treatment Resistant Schizophrenia: Increased Plasma Endomorphin 2, and κ and μ Opioid Receptors Are Associated with Interleukin-6
TLDR
In SCZ, EOS peptides/receptors may exert CIRS functions, whereas increased KOR levels may contribute to the pathophysiology of SCZ and EM2 and KOR to a non-response to treatment.
Release of endogenous dynorphin opioids in the prefrontal cortex disrupts cognition
TLDR
A mechanism for control of cortical function during opioid dependence is described and it is suggested that KOR antagonism could promote abstinence.
Chronic fatigue syndrome and fibromyalgia-like symptoms are an integral component of the phenome of schizophrenia: neuro-immune and opioid system correlates
TLDR
It is found that 45.1% of the variance in a latent vector extracted from cognitive test scores, schizophrenia symptoms and the FF score was explained by HMGB1, MOR, EM2, DKK1, and CCL11.
...
...

References

SHOWING 1-10 OF 155 REFERENCES
The dynorphin/κ-opioid receptor system and its role in psychiatric disorders
TLDR
Evidence indicating a key role for this system in modulating neurotransmission in brain circuits that subserve mood, motivation, and cognitive function is presented, suggesting that alterations in this system may contribute to affective disorders, drug addiction, and schizophrenia.
Kappa‐Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials
TLDR
If successful, KOR antagonists would represent a unique example in psychiatry where the therapeutic mechanism of a drug class is understood before it is shown to be efficacious in humans.
Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment
  • N. Crowley, T. Kash
  • Psychology, Biology
    Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 2015
Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats
TLDR
SalvA and ketamine have previously under-appreciated similarities in their behavioral effects and pharmacological profiles, and KORs might be involved in some of the cognitive abnormalities observed in psychiatric disorders such as schizophrenia.
Half a century of antipsychotics and still a central role for dopamine D2 receptors
  • S. Kapur, D. Mamo
  • Psychology, Medicine
    Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 2003
Is schizophrenia a dopamine supersensitivity psychotic reaction?
  • M. Seeman, P. Seeman
  • Psychology, Medicine
    Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 2014
...
...